Grant number: 21-3-065 | Funding period: 2022 - 2024
Completed
I Roos, S Sharmin, C Malpas, S Ozakbas, J Lechner-Scott, S Hodgkinson, R Alroughani, S Eichau Madueño, C Boz, A van der Walt, H Butzkueven, K Buzzard, O Skibina, M Foschi, F Grand’Maison, N John, P Grammond, M Terzi, J Prévost, M Barnett
2024-08-01
Background: Comparisons between cladribine and other potent immunotherapies for multiple sclerosis (MS) are lacking. Objectives: T..
A Signori, M Ponzano, T Kalincik, S Ozakbas, D Horakova, E Kubala Havrdova, R Alroughani, F Patti, J Kuhle, G Izquierdo, S Eichau, B Yamout, SJ Khoury, R Karabudak, P Grammond, P Duquette, I Roos, H Butzkueven, A Van Der Walt, MP Sormani
2024-06-17
Background To mimic as closely as possible a randomised controlled trial (RCT) and calibrate the real-world evidence (RWE) studies..
Jannis Mueller, Izanne Roos, Tomas Kalincik, Johannes Lorscheider, Edoardo Galli, Pascal Benkert, Sabine Schaedelin, Sifat Sharmin, Maximilian Einsiedler, Peter Haenni, Juerg Schmid, Jens Kuhle, Tobias Derfuss, Cristina Granziera, Tjalf Ziemssen, Timo Siepmann, Oezguer Yaldizli
2024-05-01
BACKGROUND: In patients with relapsing remitting multiple sclerosis (RRMS) on low-efficacy disease modifying therapies (DMT), the ..
S Sharmin, I Roos, S Simpson-Yap, C Malpas, MM Sánchez, S Ozakbas, D Horakova, EK Havrdova, F Patti, R Alroughani, G Izquierdo, S Eichau, C Boz, M Zakaria, M Onofrj, A Lugaresi, B Weinstock-Guttman, A Prat, M Girard, P Duquette
2023-11-01
Geographical variations in the incidence and prevalence of multiple sclerosis have been reported globally. Latitude as a surrogate..
Sifat Sharmin, Izanne Roos, Charles Malpas, Dana Horakova, Eva Havrdova, Serkan Ozakbas, Raed Alroughani, Francesco Patti, Guillermo Izquierdo, Sara Eichau Madueno, Alexandre Prat, Marc Girard, Pierre Duquette, Cavit Boz, Bassem Yammout, Samia Khoury, Alessandra Lugaresi, Marco Onofrj, Murat Terzi, Vahid Shaygannejad
2023-10-01
Tomas Kalincik, Sifat Sharmin, Izanne Roos, Mark S Freedman, Harold Atkins, Joachim Burman, Jennifer Massey, Ian Sutton, Barbara Withers, Richard Macdonell, Andrew Grigg, Oivind Torkildsen, Lars Bo, Anne Kristine Lehmann, Eva Kubala Havrdova, Eva Krasulova, Marek Trneny, Tomas Kozak, Anneke van der Walt, Helmut Butzkueven
2023-05-15
IMPORTANCE: Autologous hematopoietic stem cell transplant (AHSCT) is available for treatment of highly active multiple sclerosis (..
I Diouf, CB Malpas, S Sharmin, I Roos, D Horakova, EK Havrdova, F Patti, V Shaygannejad, S Ozakbas, G Izquierdo, S Eichau, M Onofrj, A Lugaresi, R Alroughani, A Prat, M Girard, P Duquette, M Terzi, C Boz, F Grand'Maison
2023-04-01
Background and purpose: This study assessed the effect of patient characteristics on the response to disease-modifying therapy (DM..
I Roos, I Diouf, S Sharmin, D Horakova, EK Havrdova, F Patti, V Shaygannejad, S Ozakbas, G Izquierdo, S Eichau, M Onofrj, A Lugaresi, R Alroughani, A Prat, M Girard, P Duquette, M Terzi, C Boz, F Grand’Maison, P Sola
2023-03-01
Background: In the absence of evidence from randomised controlled trials, observational data can be used to emulate clinical trial..
C Zhu, Z Zhou, I Roos, D Merlo, T Kalincik, S Ozakbas, O Skibina, J Kuhle, S Hodgkinson, C Boz, R Alroughani, J Lechner-Scott, M Barnett, G Izquierdo, A Prat, D Horakova, E Kubala Havrdova, R MacDonell, F Patti, SJ Khoury
2022-10-19
Background To compare the effectiveness and treatment persistence of ocrelizumab, cladribine and natalizumab in patients with rela..
I Roos, S Hughes, G MacDonnell, C Boz, R Alroughani, S Ozakbas, K Buzzard, O Skibina, A Van der Walt, H Butzkueven, J Lechner-Scott, J Kuhle, M Terzi, G Laureys, L Van Hijfte, N John, P Grammond, F Grand'Maison, A Soysal, F Sellebjerg
2022-10-01
T Kalincik, S Sharman, I Roos, M Freedman, H Atkins, J Burman, J Massey, I Sutton, B Withers, R Macdonell, A Grigg, O Torkildsen, L Bo, A Lehmann, D Horakova, E Havrdova, E Krasulova, M Trneny, T Kozak, A van der Walt
T Kalincik, S Sharmin, I Roos, MS Freedman, H Atkins, J Burman, J Massey, I Sutton, B Withers, R Macdonell, A Grigg, O Torkildsen, L Bo, AK Lehmann, D Horakova, EK Havrdova, E Krasulova, M Trneny, T Kozak, A van der Walt
T Kalincik, S Sharmin, I Roos, J Massey, I Sutton, B Withers, M Freedman, H Atkins, D Horakova, E Kubala Havrdova, E Krasulova, M Trneny, T Kozak, J Burman, R Macdonell, A Grigg, O Torkildsen, L Bo, AK Lehmann, B Sharrack
M Ponzano, S Ozakbas, D Horakova, E Havrdova, M Terzi, R Alroughani, F Patti, J Kuhle, G Izquierdo, S Eichau, T Kalincik, B Yamout, S Khoury, R Karabudak, C Boz, P Grammond, A Prat, M Girard, A Soysal, R Turkoglu
S Sharmin, I Roos, S Simpson-Yap, C Malpas, M Martinez Sanchez, S Ozakbas, D Horakova, EK Havrdova, F Patti, R Alroughani, V Shaygannejad, G Izquierdo, S Eichau, C Boz, M Zakaria, M Onofrj, A Lugaresi, B Weinstock-Guttman, A Prat, M Girard
Sifat Sharmin, Charles Malpas, Izanne Roos, Ibrahima Diouf, Raed Alroughani, Serkan Ozakbas, Guillermo Izquierdo, Sara Eichau, Dana Horakova, Eva Kubala Havrdova, Francesco Patti, Murat Terzi, Cavit Boz, Bassem Yamout, Samia J Khoury, Marco Onofrj, Alessandra Lugaresi, Ayse Altintas, Alexandre Prat, Marc Girard
2022-09-30
Background: Early recognition of markers of faster disability worsening in paediatric-onset multiple sclerosis (MS) is a key requi..
V Li, I Roos, M Monif, C Malpas, S Roberts, M Marriott, K Buzzard, AL Nguyen, N Seery, L Taylor, T Kalincik, T Kilpatrick
2022-07-01
Background: The coronavirus disease 2019 (COVID-19) pandemic has precipitated expansion of telemedicine in outpatient management o..
2022-05-03
S Sharmin, C Malpas, I Roos, I Diouf, R Alroughani, S Ozakbas, G Izquierdo, S Eichau, D Horakova, EK Havrdova, F Patti, M Terzi, C Boz, B Yamout, SJ Khoury, M Onofrj, A Lugaresi, A Altintas, A Prat, M Girard
2021-10-01
I Diouf, C Malpas, D Horakova, E Kubala Havrdova, F Patti, V Shaygannejad, S Ozakbas, G Izquierdo, S Eichau, M Zakaria, M Onofrj, A Lugaresi, R Alroughani, A Prat, M Girard, P Duquette, M Terzi, C Boz, F Grand'Maison, S Hamdy
2020-12-01